Document is current
Any future updates will be listed below
-
Authors
Mould, Arne W. https://orcid.org/0000-0002-2004-4348
Al-Juffali, Noura https://orcid.org/0000-0001-9190-6729
von Delft, Annette https://orcid.org/0000-0002-7699-8140
Brennan, Paul E. https://orcid.org/0000-0002-8950-7646
Tunbridge, Elizabeth M. https://orcid.org/0000-0002-2966-2281
-
Funding
Funding for this research was provided by:
Alzheimer’s Research UK
Psychiatry Consortium of the Medicines Discovery Catapult
National Institute for Health Research
- License Information
-
More Information
Article History
Accepted: 21 November 2021
First Online: 20 December 2021
Declarations
:
: EMT and AWM are in receipt of funding from Biogen and Boehringer Ingelheim via the Psychiatry Consortium of the Medicines Discovery Catapult for research on kalirin. The funders had no input into the content of this article. NAJ, AVD and PEB report no conflicts of interest.
: Not applicable.
: Not applicable.
: Not applicable.
: Not applicable.
: Not applicable.
: NAJ and AWM collated and summarised the kalirin literature. AVD and PEB wrote Section 7 (Targeting kalirin’s GEF domains). EMT wrote the remainder of the manuscript. All authors reviewed the manuscript prior to submission.
: EMT and AWM are supported by the NIHR Oxford Health Biomedical Research Centre and by funding from Biogen and Boehringer Ingelheim via the Psychiatry Consortium of the Medicines Discovery Catapult. PEB is supported by Alzheimer’s Research UK. This review was supported by the National Institute for Health Research Oxford Health Biomedical Research Centre. The views expressed are those of the authors and not necessarily those of the NHS, the NIHR or the Department of Health.
